王者荣耀网站app

Biogen traded at $211.84 this Friday September 9th, increasing $3.86 or 1.86 percent since the previous trading session. Looking back, over the last four weeks, Biogen gained 4.16 percent. Over the last 12 months, its price fell by 29.34 percent. Looking ahead, we forecast Biogen to be priced at 190.38 by the end of this quarter and at 174.40 in one year, according to 王者荣耀电竞(江西)积分排榜 global macro models projections and analysts expectations.

Stock Price
211.84
Daily Change
1.86%
Yearly
-29.34%

Ok
王者荣耀电竞(江西)积分排榜 members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The 王者荣耀电竞(江西)积分排榜 Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview
Peers Price Day Year
AbbVie 141.42 0.90 0.64% 32.56%
Acadia Pharmaceuticals 17.38 -0.04 -0.23% 8.02%
Acorda Therapeutics 0.41 0.02 3.81% -91.13%
ALKERMES 24.01 -0.05 -0.21% -21.33%
Amgen 247.69 2.24 0.91% 15.88%
Bayer 52.87 0.96 1.85% 15.50%
Biogen 211.84 3.86 1.86% -29.34%
Bluebird Bio 7.14 0.03 0.42% -60.07%
BioMarin Pharmaceutical 92.93 -0.08 -0.09% 19.17%
Bristol-Myers Squibb 70.16 0.78 1.12% 11.14%
Esperion Therapeutics 7.37 -0.16 -2.12% -37.60%
Gilead Sciences 65.28 0.18 0.28% -8.04%
Intercept Pharmaceuticals 17.00 -0.13 -0.76% 16.04%
Incyte Corp 72.20 0.48 0.67% 1.52%
Intra Cellular Therapies 52.00 -0.25 -0.48% 56.44%
Eli Lilly 317.70 2.20 0.70% 32.65%
Merck & Co 87.34 -0.08 -0.09% 18.91%
Moderna Inc 142.28 1.00 0.71% -68.34%
Marinus Pharmaceuticals 6.68 0.07 1.06% -44.79%
Neurocrine Biosciences 106.51 -0.17 -0.16% 10.10%
Novartis 79.36 0.58 0.74% 0.88%
Puma Biotechnology 2.74 0.18 7.03% -61.62%
Pfizer 47.84 0.76 1.61% 4.94%
PTC Therapeutics 53.64 -0.21 -0.39% 28.33%
Ultragenyx Pharmaceutical 49.24 1.51 3.16% -51.58%
Regeneron Pharmaceuticals 724.32 15.47 2.18% 11.35%
Sanofi 81.20 0.64 0.79% -0.82%
Seattle Genetics 155.47 2.83 1.85% 2.61%
Sangamo BioSciences 5.70 -0.07 -1.21% -40.99%
Sanofi 40.80 0.72 1.80% -15.56%
Sarepta Therapeutics 118.44 -0.80 -0.67% 47.19%
Teva Pharmaceutical Industries Ltd 3,040.00 41.00 1.37% 1.10%
United Therapeutics 223.48 -0.23 -0.10% 6.29%
Vertex Pharmaceuticals 292.11 3.12 1.08% 54.91%

Indexes Price Day Year
US500 4067 61.18 1.53% -8.77%
USND 12112 250.18 2.11% -19.87%
USNDX 12588 267.10 2.17% -18.47%

Biogen
Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company's marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; GAZYVA indicated for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of primary progressive MS (PPMS) and relapsing MS (RMS), and other anti-CD20 therapies. The Company's pipeline includes BIIB074; BAN2401; BIIB061; BIIB067, BIIB124, BIIB074, BIIB118 and TMS-007.